help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 71, No. 4 836-841
doi:10.1210/jcem-71-4-836
Copyright © 1990 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHRISTIANSEN, C.
Right arrow Articles by RIIS, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CHRISTIANSEN, C.
Right arrow Articles by RIIS, B. J.

17β-Estradiol and Continuous Norethisterone: A Unique Treatment for Established Osteoporosis in Elderly Women

CLAUS CHRISTIANSEN and BENTE JUEL RIIS

Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen DK-2600 Glostrup, Denmark

Address requests for reprints to: Claus Christiansen, M.D., Department of Clinical Chemistry, Glostrup Hospital, DK-2600 Glostrup, Denmark.

Forty women aged 64.7 ± 5.1 yr with established postmenopausal osteoporosis were blindly allocated to 1 yr's treatment with either continuous combined estrogen/progestogen therapy (2 mg estradiol + 1 mg norethisterone acetate + 500 mg calcium daily) or placebo + 500 mg calcium daily. In the group treated with hormones bone mineral density in the spine (dual photon absorptiometry) and bone mineral content in the ultradistal forearm (single photon absorptiometry) increased highly significantly by 8–10% during the 1 yr of treatment. Bone mineral content in the mid-shaft of the forearm (single photon absorptiometry) and the total body bone mineral (dual photon absorptiometry) increased by 3–5% when compared to that in the placebo group, which showed virtually unchanged values at all measurement sites. Seven of the women treated with hormones were examined after a further year of treatment. BMC increased by another 3–6%, reaching a 12% increase in bone mineral density in the spine after 2 yr of treatment.

Biochemical estimates of bone resorption (fasting urinary calcium and hydroxyproline) and bone formation (serum alkaline phosphatase and plasma osteocalcin), decreased significantly (P < 0.001) in the group treated with hormones, but remained unchanged in the placebo group. The reduction in indices of bone resorption was more pronounced than that in bone formation after one year, indicating a positive bone balance. No further changes were seen in these bone turnover parameters during the second year of treatment. In the group treated with hormones, serum levels of triglycerides, total cholesterol, and low density lipoprotein cholesterol decreased by about 12% (P < 0.05-P < 0.01), whereas high density lipoprotein cholesterol decreased by about 8% (P < 0.001). The high density lipoprotein cholesterol/low density lipoprotein cholesterol ratio was unchanged. The hormone treatment did not produce any major side effects, and only minor bleedings were experienced by a few women.

The present study demonstrates that treatment with female sex hormones in this particular combination is a realistic approach to the treatment of women with established postmenopausal osteoporosis.

Received January 16, 1990.




This article has been cited by other articles:


Home page
AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. L. S. Gass, S. S. Bassuk, and J. E. Manson
Reassessing Benefits and Risks of Hormone Therapy
American Journal of Lifestyle Medicine, January 1, 2009; 3(1): 29 - 43.
[Abstract] [PDF]


Home page
J EndocrinolHome page
J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios
The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites
J. Endocrinol., June 1, 2007; 193(3): 493 - 504.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Collins, M. Flather, B. Lees, R. Mister, A. J. Proudler, J. C. Stevenson, and on behalf of the WHISP (Women's Hormone Interventi
Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study
Eur. Heart J., September 1, 2006; 27(17): 2046 - 2053.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki
Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell, and A. Cranney
V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women
Endocr. Rev., August 1, 2002; 23(4): 529 - 539.
[Full Text] [PDF]


Home page
JAMAHome page
D. T. Villareal, E. F. Binder, D. B. Williams, K. B. Schechtman, K. E. Yarasheski, and W. M. Kohrt
Bone Mineral Density Response to Estrogen Replacement in Frail Elderly Women: A Randomized Controlled Trial
JAMA, August 15, 2001; 286(7): 815 - 820.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Alexandersen, B. J. Riis, J. A. Stakkestad, P. D. Delmas, and C. Christiansen
Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 755 - 760.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley
The Contribution of Testosterone to Skeletal Development and Maintenance: Lessons from the Androgen Insensitivity Syndrome
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1032 - 1037.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
P. Ravn, M. Bidstrup, R. D. Wasnich, J. W. Davis, M. R. McClung, A. Balske, C. Coupland, O. Sahota, A. Kaur, M. Daley, et al.
Alendronate and Estrogen-Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial
Ann Intern Med, December 21, 1999; 131(12): 935 - 942.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Alexandersen, B. J. Riis, and C. Christiansen
Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3013 - 3020.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Vestergaard, A. P. Hermann, H. Ørskov, and L. Mosekilde
Effect of Sex Hormone Replacement on the Insulin-Like Growth Factor System and Bone Mineral: A Cross-Sectional and Longitudinal Study in 595 Perimenopausal Women Participating in the Danish Osteoporosis Prevention Study
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2286 - 2290.
[Abstract] [Full Text]


Home page
JAMAHome page
S. L. Greenspan
A 73-Year-Old Woman With Osteoporosis
JAMA, April 28, 1999; 281(16): 1531 - 1540.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Alexandersen, J. Haarbo, I. Sandholdt, M. Shalmi, H. Lawaetz, and C. Christiansen
Norethindrone Acetate Enhances the Antiatherogenic Effect of 17ß-Estradiol : A Secondary Prevention Study of Aortic Atherosclerosis in Ovariectomized Cholesterol-Fed Rabbits
Arterioscler Thromb Vasc Biol, June 1, 1998; 18(6): 902 - 907.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. L. Schneider, E. L. Barrett-Connor, and D. J. Morton
Timing of Postmenopausal Estrogen for Optimal Bone Mineral Density: The Rancho Bernardo Study
JAMA, February 19, 1997; 277(7): 543 - 547.
[Abstract] [PDF]


Home page
JAMAHome page
The Writing Group for the PEPI Trial
Effects of Hormone Therapy on Bone Mineral Density: Results From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
JAMA, November 6, 1996; 276(17): 1389 - 1396.
[Abstract] [PDF]


Home page
NEJMHome page
B. Ettinger and D. Grady
The Waning Effect of Postmenopausal Estrogen Therapy on Osteoporosis
N. Engl. J. Med., October 14, 1993; 329(16): 1192 - 1193.
[Full Text]


Home page
Arch Intern MedHome page
G. E.-H. Fuleihan, E. M. Brown, K. Curtis, M. J. Berger, B. M. Berger, R. Gleason, and M. S. LeBoff
Effect of Sequential and Daily Continuous Hormone Replacement Therapy on Indexes of Mineral Metabolism
Arch Intern Med, September 1, 1992; 152(9): 1904 - 1909.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
E. G. Lufkin, H. W. Wahner, W. M. O'Fallon, S. F. Hodgson, M. A. Kotowicz, A. W. Lane, H. L. Judd, R. H. Caplan, and B. L. Riggs
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Ann Intern Med, July 1, 1992; 117(1): 1 - 9.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
S. M. Ott
Estrogen Therapy for Osteoporosis--Even in the Elderly
Ann Intern Med, July 1, 1992; 117(1): 85 - 86.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society